Drug of Choice | GenomeWeb

Drug of Choice

The Wall Street Journal reports that GlaxoSmithKline is seeking direction from healthcare officials in France, Italy, Spain, and the UK on what drugs under development at Glaxo should be pursued. The pharma company hopes that this will give rise to more drugs that the healthcare systems will buy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.